Literature DB >> 11122815

The role of carcinoembryonic antigen monitoring in management of colorectal cancer.

M F Mulcahy1, A B Benson.   

Abstract

Carcinoembryonic antigen (CEA) is an important tool in the management of colorectal cancer. Its use as a prognostic indicator in resectable disease remains controversial but may be improved with molecular detection of the antigen. In monitoring patients after resection, CEA can be the first sign of a potentially curable recurrence. It can also be useful in assessing tumor response in patients being treated for metastases without easily measurable disease. CEA alone cannot dictate the type or duration of treatment but may be used in addition to standard monitoring tests.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 11122815     DOI： 10.1007/s11912-999-0029-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  30 in total

1.  Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer.

Authors:  H J Wanebo; B Rao; C M Pinsky; R G Hoffman; M Stearns; M K Schwartz; H F Oettgen
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

2.  Prospective randomised trial of early cytotoxic therapy for recurrent colorectal carcinoma detected by serum CEA.

Authors:  K R Hine; P W Dykes
Journal:  Gut       Date:  1984-06       Impact factor: 23.059

3.  The use of preoperative plasma CEA levels for the Stratification of patients after curative resection of colorectal cancers.

Authors:  R Goslin; G Steele; J Macintyre; R Mayer; P Sugarbaker; K Cleghorn; R Wilson; N Zamcheck
Journal:  Ann Surg       Date:  1980-12       Impact factor: 12.969

4.  The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer.

Authors:  C G Moertel; J R O'Fallon; V L Go; M J O'Connell; G S Thynne
Journal:  Cancer       Date:  1986-08-01       Impact factor: 6.860

5.  Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma.

Authors:  J P Arnaud; C Koehl; M Adloff
Journal:  Dis Colon Rectum       Date:  1980-04       Impact factor: 4.585

Review 6.  Carcinoembryonic antigen.

Authors:  R H Fletcher
Journal:  Ann Intern Med       Date:  1986-01       Impact factor: 25.391

7.  Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial.

Authors:  J T Mäkelä; S O Laitinen; M I Kairaluoma
Journal:  Arch Surg       Date:  1995-10

8.  A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results.

Authors:  P H Sugarbaker; F J Gianola; A Dwyer; N R Neuman
Journal:  Surgery       Date:  1987-07       Impact factor: 3.982

Review 9.  Value of carcinoembryonic antigen in the management of colorectal cancer.

Authors:  J Y Wang; R Tang; J M Chiang
Journal:  Dis Colon Rectum       Date:  1994-03       Impact factor: 4.585

10.  The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer.

Authors:  J L McCall; R B Black; C A Rich; J R Harvey; R A Baker; J M Watts; J Toouli
Journal:  Dis Colon Rectum       Date:  1994-09       Impact factor: 4.585
View more
  3 in total

1.  Systematic follow-up after curative surgery for colorectal cancer in Norway: a population-based audit of effectiveness, costs, and compliance.

Authors:  Hartwig Körner; Kjetil Söreide; Pål J Stokkeland; Jon Arne Söreide
Journal:  J Gastrointest Surg       Date:  2005-03       Impact factor: 3.452

2.  Inferring novel genes related to colorectal cancer via random walk with restart algorithm.

Authors:  Sheng Lu; Zheng-Gang Zhu; Wen-Cong Lu
Journal:  Gene Ther       Date:  2019-07-15       Impact factor: 5.250

3.  Prognostic significance of Wnt-1, β-catenin and E-cadherin expression in advanced colorectal carcinoma.

Authors:  Aleksandra Stanczak; Rafal Stec; Lubomir Bodnar; Wojciech Olszewski; Marzena Cichowicz; Wojciech Kozlowski; Cezary Szczylik; Tadeusz Pietrucha; Maciej Wieczorek; Monika Lamparska-Przybysz
Journal:  Pathol Oncol Res       Date:  2011-06-16       Impact factor: 3.201
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.